The drug is already widely used and covered to treat Type 2 diabetes. The FDA's decision means Ozempic can now be used to reduce the risk of kidney disease worsening, kidney failure, and death from ...

The drugs have become popular for their significant weight-loss effects, but their high cost has made them inaccessible for ...

These drugs promise faster results with fewer side effects, and in some cases, reversal or slows the disease progression.

The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...

Rising chronic kidney disease prevalence and morbidity rates in 2023 make CKD the ninth leading cause of death globally, ...

The benefits of SGLT2 inhibitors on kidney disease progression in individuals irrespective of diabetes or albuminuria status ...

For a limited time, patients in the US can get the first two doses of authentic, FDA-approved Wegovy(R) and Ozempic(R) for only $199 each beginning November 17, 2025 -- Also effective November 17, ...

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

It is important for individuals who have type 2 diabetes to understand the connected impact that diabetes has on their ...

Adding an investigational nonsteroidal mineralocorticoid receptor antagonist (MRA) to an SGLT2 inhibitor led to a superior ...

Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on ...